Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Uncovering cases of early HCV infection in HIV-positive men

While screening the blood samples of patients for HCV antibodies can be useful, a new study suggests that in some cases such antibodies may not appear for several months after HCV infection has occurred. In such cases, acute HCV infection might be missed if antibody tests alone are used for screening - RNA testing should be used to screen HCV infection.

Published
17 September 2014
From
CATIE
Gilead Deal to Sell Sovaldi in Poor Countries Meets Criticism

more than three dozen patient advocacy groups say the licensing deals do not go far enough, because the deals excludes many middle-income countries – such as Brazil, China, Turkey, Thailand and Ukraine – where governments and individuals may not be able to afford the Gilead drug. The patient groups are concerned the licenses will preclude the generic drug makers from selling lower-cost versions to those countries and potentially excluding millions of patients with hepatitis C from gaining access to treatment.

Published
16 September 2014
From
Pharmalot
Clash between state, drugmaker heats up as Legislature takes up Hepatitis C cost

Citing the 12-week treatment cost of $84,000, Oregon officials want to put strict new restrictions on access to the drug, especially for those in earlier stages of the disease. Commercial insurers already have some access rules, but are watching the state's battle closely.

Published
16 September 2014
From
The Oregonian
Gilead signs pact with 7 firms for cheap copies of hepatitis C drug

Gilead's licensing agreement with firms including India's Cipla Ltd and Ranbaxy Laboratories Ltd clears the way for the launch of a cheap generic version of the drug in 91 developing countries that make up 54 percent of the total global hepatitis burden.

Published
15 September 2014
From
Reuters
AbbVie 3D hepatitis C regimen is well-tolerated in Phase 3 trials

AbbVie's 3D hepatitis C regimen containing ABT-450, ombitasvir, and dasabuvir was generally well-tolerated in the Phase 3 SAPPHIRE trials, according to a pooled analysis presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy last week in Washington, DC.

Published
15 September 2014
From
HIVandHepatitis.com
Gilead to raise price for new hepatitis C drug above $84000

The fixed-dose regimen version of Gilead Sciences Inc's $84,000 hepatitis C drug, already under fire for its record-breaking costs, is going to be even more expensive.

Published
15 September 2014
From
Reuters
Simeprevir in hepatitis C: added benefit for certain patients

Added benefit for untreated and relapsed patients with unclear extent; major added benefit for non-responders; missing data for patients with HIV coinfection and genotype 4 patients.

Published
10 September 2014
From
German Institute for Quality and Efficiency in Health Care
Gilead close to sending $84,000 drug to poor countries

Gilead Sciences Inc. is close to a pact with generic drugmakers to bring low-cost versions of its $84,000 hepatitis C drug Sovaldi to about 80 developing countries including India, Indonesia, and Pakistan.

Published
09 September 2014
From
Bloomberg
HIV-Negative Gay Men May Acquire Hepatitis C Sexually

HIV-negative men who have sex with men (MSM) are apparently at risk for sexual acquisition of hepatitis C virus (HCV), the National AIDS Treatment Advocacy Project reports. Their risk factors are likely similar to those of HIV-positive men. Researchers at Chelsea and Westminster Hospital in London conducted a retrospective study of the clinic’s patients in which they identified 44 acute cases of hep C among HIV-negative MSM between January 2010 and December 2013.

Published
09 September 2014
From
Aidsmeds.com
US: HIV medical organizations challenge insurer restrictions to HCV treatment

The American Academy of HIV Medicine (AAHIVM) and the HIV Medicine Association (HIVMA), the two largest professional associations representing HIV clinicians in the U.S., are challenging new health plan cost control policies barring many qualified HIV care providers from prescribing certain medications that treat hepatitis C (HCV).

Published
04 September 2014
From
EATG / AAHIVM / HIVMA

Filter by country